Reading RZLT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track RZLT free→Reading RZLT? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track RZLT free→QuarterlyIQ Insights · RZLT
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 12, 2026, Rezolute, Inc. issued a press release announcing its financial results for the third quarter ended March 31, 2026. A copy of this press release is attached hereto as Exhibit 99.1. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that sec…
Results of Operations and Financial Condition. On February 12, 2026, Rezolute, Inc. issued a press release announcing its financial results for the second quarter ended December 31, 2025. A copy of this press release is attached hereto as Exhibit 99.1. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of…
Results of Operations and Financial Condition. On November 6, 2025, Rezolute, Inc. issued a press release announcing its financial results for the first quarter ended September 30, 2025. A copy of this press release is attached hereto as Exhibit 99.1. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of…
Entry Into Material Definitive Agreement
Termination of a Material Definitive Agreement. On October17, 2025, the Company delivered written notice to Jefferies LLC indicating that it is terminating the Open Market Sale Agreement by and between the Company and Jefferies LLC, dated November 14, 2023, effective as of October 24, 2025. The Company filed with the SEC a prospectus supplement, which formed a part of the Registration Statement on Form S-3 (File No. 333-275562), declared effective by the SEC on November 29, 2023, relating to…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Amendment to Employment Agreements On October 17, 2025, Rezolute, Inc. (the “Company”), Nevan C. Elam, the Company’s Chief Executive Officer, Brian Roberts, the Company’s Chief Medical Officer, Daron Evans, the Company’s Chief Financial Officer and Sunil Karnawat, the Company’s Chief Commercial Officer each entered into amendments to their respecti…
Results of Operations and Financial Condition. On September 17, 2025, Rezolute, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended June 30, 2025. A copy of this press release is attached hereto as Exhibit 99.1. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (c) Election of Chief Commercial Officer. On August 18, 2025, Rezolute, Inc. (the “ Company ”) appointed Sunil Karnawat, age 58, as Chief Commercial Officer of the Company, Dr. Karnawat brings over two decades of executive leadership experience in the biotech, pharma, medical device, and diagnostics industries. Since 2024, Dr. Karnawat served as Vi…
Entry into a Material Definitive Agreement.
Other Events. As previously reported in the Company’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on April 23, 2025, certain insiders of the Company agreed to purchase up to $10,000,000 of shares of Common Stock at a price of $3.25 per share in a private placement (the “ Private Placement ”). On June 13, 2025, pursuant to the terms of a Securities Purchase Agreement, by and among the Company and certain investors (collectively, the “ Investors ”), the Company…
of the Initial Filing to disclose that, on June 10, 2025, the Board appointed Mr. Harris as a member of the Compensation Committee, effective as of July 1, 2025. Except as set forth herein, this Current Report on Form 8-K/A does not amend, modify or update the disclosure contained in the Initial Filing. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorize…
Unregistered Sales of Equity Securities. The disclosures set forth below in
Results of Operations and Financial Condition. On May 13, 2025, Rezolute, Inc. issued a press release announcing its financial results for the third quarter ended March 31, 2025. A copy of this press release is attached hereto as Exhibit 99.1. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that sec…
Other Events. Private Placement In a transaction separate from the Registered Direct Offering, certain insiders of the Company have agreed to purchase up to $10,000,000 of shares of Common Stock at a price of $3.25 per share, which reflects the Registered Direct Offering price (the “ Private Placement ”) which exceeds the definition of market value for Nasdaq Listing Rule 5635(c) purposes. The shares of Common Stock offered in the Private Placement were offered pursuant to an exemption from r…
Entry into a Material Definitive Agreement. Registered Direct Offering On April 23, 2025, Rezolute, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Guggenheim Securities, LLC (“ Guggenheim Securities ”), as representative of the underwriters listed therein (the “ Underwriters ”), relating to the issuance and sale in a registered direct offering (the “ Registered Direct Offering ”) by the Company of (i) 20,786,923 shares (the “ Shares ”) of t…
Unregistered Sales of Equity Securities. The information under
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) Election of New Director. On March 25, 2025, the Board of Directors (the “Board”) of Rezolute, Inc. (the “Company”) upon the recommendation of the Company’s nominating and corporate governance committee elected Erik Harris to the Board, effective March 25, 2025 (the “Effective Date”). The Board determined that Mr. Harris qualifies as “independe…
Results of Operations and Financial Condition. On February 12, 2025, Rezolute, Inc. issued a press release announcing its financial results for the second quarter ended December 31, 2024. A copy of this press release is attached hereto as Exhibit 99.1. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.